Primary Myelofibrosis (PMF) — a BCR-ABL1–negative myeloproliferative neoplasm defined by clonal hematopoietic stem cell proliferation, progressive bone marrow fibrosis ranging from prefibrotic (pre-PMF) through overt fibrotic stages (MF-1 through MF-3), and the clinical triad of splenomegaly from extramedullary hematopoiesis, constitutional symptoms (fatigue, night sweats, weight loss), and peripheral blood cytopenias — is classified by its driver mutation landscape: JAK2 V617F (approximately 50–60% of patients), CALR exon 9 insertions/deletions (approximately 25–30%), MPL W515L/K exon 10 mutations (approximately 5–8%), and triple-negative PMF (lacking all three driver mutations, approximately 7–10%) with higher-risk clinical behavior; pathologic diagnosis requires bone marrow trephine biopsy demonstrating megakaryocytic proliferation and atypia (cloud-like nuclei, clustering, and naked megakaryocyte nuclei in overt PMF) with variable reticulin and collagen fibrosis graded on the WHO 0–3 scale, accompanied by leukoerythroblastic peripheral blood smear, elevated serum lactate dehydrogenase, splenomegaly on clinical examination or imaging, and driver mutation molecular profiling via allele-specific PCR or NGS panel including JAK2 exon 12, JAK2 V617F, CALR exon 9, MPL exon 10, and high-molecular-risk co-mutations (ASXL1, EZH2, IDH1/2, SRSF2, U2AF1Q157) that inform prognosis and treatment intensity. Risk stratification employs the DIPSS (Dynamic International Prognostic Scoring System) incorporating age, hemoglobin, leukocyte count, constitutional symptoms, and circulating blasts, or the DIPSS-Plus incorporating transfusion need, platelet count, and unfavorable cytogenetics, or the MIPSS70+v2.0 integrating molecular mutation data with clinical and pathologic variables to define very low, low, intermediate-1, intermediate-2, and high-risk disease groups with median overall survival ranging from decades in very low-risk disease to under 2 years in high-risk PMF. Treatment of PMF is stratified by risk: symptomatic low-risk and all intermediate-to-high-risk patients are candidates for JAK1/2 inhibitor therapy with ruxolitinib (achieving spleen volume reduction ≥35% by MRI in 42% of patients at 48 weeks and symptom improvement in the majority), fedratinib (for ruxolitinib-resistant or -intolerant patients), pacritinib (for thrombocytopenic patients with platelets below 50×10⁹/L), or momelotinib (with anemia benefit through ACVR1/ALK2 inhibition), while allogeneic hematopoietic stem cell transplantation — the only potentially curative therapy — is offered to eligible intermediate-2 and high-risk patients under age 70 with appropriate donor availability and adequate performance status.
Primary myelofibrosis technology platforms — whether supporting hematology-pathology laboratories performing bone marrow trephine biopsy evaluation with MF grading and megakaryocytic morphology assessment, molecular diagnostics platforms running JAK2/CALR/MPL mutation profiling and high-risk co-mutation NGS panels, hematology-oncology platforms managing JAK inhibitor therapy with spleen volume MRI response assessment and CBC toxicity monitoring, radiology platforms providing MRI-based spleen volume quantification and CT-based extramedullary hematopoiesis surveillance, hematopoietic stem cell transplantation programs managing allogeneic transplant conditioning and engraftment monitoring for high-risk PMF, or clinical trial platforms managing enrollment in emerging JAK inhibitor combination studies — must maintain availability and performance standards matching PMF's molecular complexity, chronic treatment toxicity monitoring requirements, transplant coordination demands, and prolonged surveillance obligations. This guide explains why primary myelofibrosis tech platforms require dedicated monitoring, what components to monitor, and how to build an alerting strategy calibrated to the molecular diagnostics, JAK inhibitor management, spleen response assessment, and transplant coordination of modern PMF care.
Why Primary Myelofibrosis Tech Platforms Require Specialized Monitoring Attention
Primary myelofibrosis management is driven by the molecular diagnostic imperative of characterizing driver mutation status and high-risk co-mutations from bone marrow biopsy material at diagnosis and at disease evolution checkpoints; the ongoing treatment management imperative of CBC and clinical toxicity monitoring for patients on ruxolitinib, fedratinib, pacritinib, or momelotinib; the spleen response imperative of serial MRI-based spleen volume quantification to assess treatment efficacy; and the transplant coordination imperative of managing conditioning, engraftment, and graft-versus-host disease monitoring for high-risk patients who proceed to allogeneic SCT. Technology failures in these domains create disruptions calibrated to the molecular, clinical, and transplant consequences of a myeloproliferative neoplasm with a wide survival spectrum and an evolving treatment paradigm.
Bone marrow pathology platforms are central to diagnosis and disease evolution assessment. Trephine biopsy MF grade (WHO 0–3 reticulin and collagen fibrosis) and megakaryocytic atypia assessment determine the pre-PMF versus overt PMF distinction and document disease progression toward blast phase transformation — findings that govern treatment intensification decisions. Monitor bone marrow pathology platforms at 1-minute intervals during business hours.
Molecular diagnostics platforms drive risk stratification and treatment selection. JAK2 V617F allele burden quantification, CALR exon 9 mutation detection, MPL exon 10 mutation analysis, and high-molecular-risk co-mutation NGS panels (ASXL1, EZH2, IDH1/2, SRSF2, U2AF1Q157) are required at diagnosis and at clinical inflection points to guide MIPSS70+v2.0 risk reclassification and transplant referral. Monitor molecular diagnostics platforms at 1-minute intervals during business hours.
MRI spleen volume monitoring platforms assess JAK inhibitor treatment response. MRI-based spleen volume quantification at baseline, 12 weeks, and 24 weeks defines spleen volume reduction (SVR ≥35% = response) that is the primary endpoint of JAK inhibitor therapy and the standard by which ruxolitinib continuation, dose adjustment, or switch to an alternative JAK inhibitor is evaluated. Monitor imaging platforms during scheduled MRI assessment windows.
Hematology-oncology platforms manage chronic JAK inhibitor toxicity. CBC monitoring for ruxolitinib-associated anemia and thrombocytopenia, fedratinib-associated Wernicke encephalopathy risk (thiamine supplementation protocol), pacritinib bleeding risk in thrombocytopenic patients, and JAK inhibitor discontinuation syndrome prevention require reliable platform availability during clinic encounter and monitoring hours. Monitor oncology platforms during clinical hours.
Transplant platforms coordinate allogeneic SCT for high-risk PMF. HLA typing, donor search, myeloablative or reduced-intensity conditioning regimen administration, stem cell infusion, engraftment monitoring, and GVHD prevention and treatment require coordinated platform availability across the transplant program at time-critical treatment junctures. Monitor transplant platforms during clinical hours.
What to Monitor on a Primary Myelofibrosis Tech Platform
Bone Marrow Pathology and Morphology Assessment
Monitor bone marrow trephine biopsy histomorphologic records (cellularity, megakaryocytic proliferation and clustering, megakaryocyte nuclear morphology — cloud-like nuclei, hyperchromatic nuclei, naked megakaryocyte nuclei), reticulin fibrosis grade records (MF-0 through MF-3 WHO grading), collagen fibrosis assessment by Masson trichrome, osteosclerosis evaluation, leukoerythroblastic smear morphology review, blast percentage quantification for accelerated or blast phase transformation assessment, bone marrow aspirate differential count records, flow cytometry blast and progenitor cell immunophenotyping records, and cytogenetic karyotype records (del20q, +8, der(6)t(1;6), -7/del7q as unfavorable cytogenetics in DIPSS-Plus) at 1-minute intervals during business hours. Alert immediately — bone marrow pathology platform failures delay MF grade determination on trephine biopsy material where the WHO MF-0/MF-1 versus MF-2/MF-3 grading distinction has direct implications for risk scoring and transplant referral timing.
Molecular Diagnostics and High-Risk Co-Mutation Profiling
Monitor JAK2 V617F allele burden quantification records by allele-specific PCR or digital droplet PCR, CALR exon 9 insertion/deletion mutation analysis records (type 1 del52bp versus type 2 ins5bp) with prognostic distinction documentation, MPL W515L/K/N/A exon 10 mutation analysis records, ASXL1 exon 12 mutation status records, EZH2 exon 16–20 mutation records, IDH1 R132 and IDH2 R140/R172 mutation records, SRSF2 P95 mutation records, U2AF1 Q157 mutation records, TP53 mutation records for blast phase evolution risk, sequential JAK2 allele burden monitoring records for treatment response assessment, and NGS panel variant allele frequency longitudinal tracking records at 1-minute intervals during business hours. Alert immediately — molecular diagnostics platform failures delay MIPSS70+v2.0 risk stratification based on high-molecular-risk co-mutation data where ASXL1, EZH2, IDH1/2, SRSF2, and U2AF1Q157 mutations define a population with inferior survival warranting early transplant referral.
JAK Inhibitor Therapy and Toxicity Monitoring
Monitor ruxolitinib dose and schedule administration records (starting dose 20mg twice daily for platelets ≥200×10⁹/L, 15mg for 100–200, 5mg for 50–100), CBC monitoring records for anemia (dose reduction thresholds at hemoglobin <10 g/dL) and thrombocytopenia (dose reduction below platelets 50×10⁹/L), opportunistic infection prophylaxis documentation (PCP, herpes zoster reactivation), fedratinib thiamine supplementation protocol and encephalopathy monitoring records, pacritinib hemorrhagic event and QTc prolongation monitoring records, momelotinib anemia response (hemoglobin improvement and transfusion independence rate) and peripheral neuropathy monitoring records, JAK inhibitor discontinuation syndrome recognition and taper protocol documentation, constitutional symptom assessment (MPN-SAF TSS scoring at each visit), and erythropoiesis-stimulating agent or luspatercept anemia management records at 1-minute intervals during clinical encounters. Alert immediately — platform failures during active JAK inhibitor toxicity monitoring create patient safety risks in a patient population chronically dependent on outpatient CBC-guided dose management.
Spleen Imaging and Response Assessment
Monitor MRI spleen volume quantification records (baseline pre-treatment, 12-week, 24-week, and subsequent assessments), SVR35 (≥35% spleen volume reduction) and SVR50 response documentation, CT abdomen/pelvis imaging records for anatomic spleen evaluation and extramedullary hematopoiesis documentation (periportal, periaortic, thoracic, hepatic, and intracranial EM hematopoiesis), ultrasound spleen size measurement records (longitudinal spleen length as surrogate when MRI is unavailable), hepatomegaly assessment records, portal hypertension evaluation (esophageal varices, ascites) in advanced fibrotic disease, and bone scan records for osteosclerosis or accelerated disease imaging at 1-minute intervals during imaging sessions. Alert immediately — imaging platform failures at scheduled MRI spleen volume assessment timepoints delay SVR35 response determination that governs JAK inhibitor continuation or therapeutic switch.
Hematopoietic Stem Cell Transplantation
Monitor HLA high-resolution typing records (patient and donor), unrelated donor search coordination records, MUD and MMUD transplant feasibility assessment documentation, reduced-intensity conditioning regimen administration records (fludarabine/busulfan-based RIC for age >50 or comorbidities), myeloablative conditioning records for younger patients with high-risk disease, GVHD prophylaxis administration records (tacrolimus, mycophenolate, post-transplant cyclophosphamide), engraftment monitoring records (serial CBC for neutrophil engraftment ≥0.5×10⁹/L, platelet engraftment), chimerism assessment records (CD3 and CD33 lineage chimerism by STR), acute and chronic GVHD grading and treatment records, and infectious complication prophylaxis and monitoring during aplasia at 1-minute intervals during transplant clinical encounters. Alert on sustained failures — transplant platform failures during conditioning or stem cell infusion disrupt an irreversible treatment sequence with direct patient safety implications.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Primary myelofibrosis programs coordinate across hematology-pathology (bone marrow grading), molecular diagnostics (JAK2/CALR/MPL/NGS), hematology-oncology (JAK inhibitor management), radiology (MRI spleen volume, CT EMH surveillance), and transplant hematology — authentication failures simultaneously block every clinician whose access to MF grade reports, mutation profiles, CBC toxicity trends, spleen MRI response data, and transplant documentation is required for coordinated MPN management.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, bone marrow pathology reporting platforms, molecular diagnostics reporting systems, oncology management platforms, MRI spleen volume reporting systems, and transplant coordination platforms. Certificate errors disrupt the diagnostics, molecular reporting, JAK inhibitor management, imaging response assessment, and transplant coordination workflows central to PMF care.
HIPAA and Oncology Data Privacy Considerations
Primary myelofibrosis technology platforms handle sensitive PHI including comprehensive bone marrow pathology and MF grading records, JAK2/CALR/MPL driver mutation and high-risk co-mutation NGS panel results with prognostic implications, longitudinal JAK inhibitor dose and CBC toxicity monitoring records, MRI spleen volume quantification results that directly determine treatment response categorization, allogeneic transplant conditioning and GVHD records, and long-term disease surveillance PHI. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components managing this PHI.
For platforms managing molecular mutation profiling records that document JAK2 allele burden, CALR mutation type, and high-risk co-mutation status — findings that form the basis for MIPSS70+v2.0 risk stratification, transplant eligibility determination, and clinical trial enrollment — integrity and availability standards must reflect the clinical weight of this molecular PHI. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance for hematology-oncology programs managing the intersection of bone marrow pathology, molecular diagnostics, JAK inhibitor pharmacotherapy, spleen imaging response, and transplant PHI.
Alerting Strategy for Primary Myelofibrosis Tech Platforms
Immediate alerting during JAK inhibitor toxicity monitoring: CBC and dose management platforms, ruxolitinib/fedratinib/pacritinib/momelotinib administration documentation, opportunistic infection prophylaxis monitoring, and constitutional symptom assessment platforms during active clinical encounter hours.
Immediate alerting during MRI spleen volume assessment windows: MRI acquisition and spleen volume quantification platforms at scheduled 12-week and 24-week SVR35 assessment timepoints.
Immediate alerting during transplant conditioning and stem cell infusion: Conditioning regimen administration platforms, stem cell infusion documentation, and engraftment monitoring systems during active transplant sessions.
Immediate business-hours alert: Bone marrow pathology (MF grading, megakaryocytic morphology), JAK2/CALR/MPL mutation profiling, and high-risk co-mutation NGS panel reporting platforms.
Sustained-failure alert (10–15 minutes): CT EMH surveillance scheduling, chimerism assessment, and long-term disease surveillance scheduling platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms primary myelofibrosis platform availability from the geographies where high-volume MPN programs with bone marrow pathology expertise, molecular risk stratification, JAK inhibitor management experience, and allogeneic transplant capability concentrate.
Status Page for Primary Myelofibrosis Care Team Communication
A real-time status page gives hematologists-oncologists managing ruxolitinib CBC dose titration, pathologists issuing bone marrow MF grade reports, molecular diagnostics labs reporting JAK2 allele burden and co-mutation profiles, radiologists quantifying MRI spleen volumes, and transplant teams coordinating conditioning immediate platform visibility without requiring inbound IT support contact. During an MRI platform outage on the day of scheduled 12-week spleen volume reassessment, a status page enables immediate contingency rescheduling without treatment delay.
Include the status page URL in JAK inhibitor toxicity monitoring protocols, bone marrow biopsy laboratory emergency access procedures, MRI spleen volume assessment contingency procedures, and transplant conditioning downtime procedures.
Vigilmon Setup for Primary Myelofibrosis Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Bone marrow pathology / MF grading | 1 min | Slack + PagerDuty (business hours) | | JAK2/CALR/MPL mutation profiling / co-mutation NGS | 1 min | Slack + PagerDuty (business hours) | | Ruxolitinib / fedratinib CBC toxicity monitoring | 1 min | Slack + PagerDuty (clinical hours) | | MRI spleen volume quantification / SVR35 assessment | 1 min | Slack + PagerDuty (imaging hours) | | JAK inhibitor administration / pharmacy verification | 1 min | Slack + PagerDuty (clinical hours) | | Transplant conditioning / stem cell infusion | 1 min | Slack + PagerDuty (transplant hours) | | GVHD prophylaxis / engraftment monitoring | 2 min | Slack (transplant hours) | | CT EMH surveillance scheduling | 2 min | Slack (business hours) | | Chimerism / post-transplant molecular monitoring | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure bone marrow pathology and MF grading platforms with immediate business-hours alerting
- Add JAK2/CALR/MPL mutation profiling and high-risk co-mutation NGS platforms with immediate business-hours alerting
- Configure ruxolitinib and alternative JAK inhibitor CBC toxicity monitoring with immediate clinical-hours alerting
- Add MRI spleen volume quantification platforms with immediate alerting during scheduled SVR35 assessment windows
- Configure transplant conditioning and stem cell infusion documentation with immediate alerting during active transplant sessions
- Add GVHD prophylaxis and engraftment monitoring with sustained-failure alerting during transplant clinical hours
- Configure CT EMH surveillance scheduling and chimerism monitoring with sustained-failure alerting
- Enable SSL certificate monitoring across all clinical, diagnostics, molecular, imaging, transplant, and surveillance domains
- Add the status page URL to JAK inhibitor management protocols, bone marrow biopsy emergency procedures, MRI contingency procedures, and transplant downtime procedures
Conclusion
Primary myelofibrosis technology platforms are embedded in clinical decisions where bone marrow pathology platform availability when a hematopathologist must grade reticulin fibrosis on a trephine biopsy — where the WHO MF-0 versus MF-2 distinction determines whether a patient is managed with watchful waiting or JAK inhibitor therapy with transplant referral consideration — cannot be delayed by pathology platform unavailability; where JAK2 allele burden and high-risk co-mutation NGS platform availability at the clinical inflection point when MIPSS70+v2.0 risk reclassification determines whether ruxolitinib continuation or transplant referral is the appropriate next step cannot be interrupted by molecular diagnostics platform failure; and where MRI spleen volume quantification platform availability at the scheduled 12-week and 24-week assessment windows that define SVR35 response — the benchmark by which ruxolitinib continuation, dose escalation, or switch to fedratinib, pacritinib, or momelotinib is determined — cannot be disrupted by imaging platform downtime. A bone marrow pathology platform that fails when the MF grade on trephine biopsy determines risk stratification and transplant timing, a molecular diagnostics platform unavailable when ASXL1 co-mutation data is needed for MIPSS70+v2.0 scoring, a JAK inhibitor CBC toxicity monitoring platform inaccessible when dose reduction thresholds are being evaluated — these are not IT incidents. They are clinical disruptions in the management of a myeloproliferative neoplasm where molecular precision, treatment-response-adapted management, and chronic toxicity monitoring are the pillars of optimal long-term outcomes.
Uptime monitoring gives primary myelofibrosis tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to hematopathology programs, molecular diagnostics laboratories, hematology-oncology services, radiology departments, transplant programs, and compliance auditors that platform operational reliability matches the molecular complexity, JAK inhibitor toxicity management requirements, spleen response assessment demands, and transplant coordination obligations of modern primary myelofibrosis care.
Start monitoring your primary myelofibrosis care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #myelofibrosis #PMF #JAK2 #CALR #MPL #ruxolitinib #MPN #bonemarrow #splenomegaly #stemcelltransplant #hematologyoncology #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre